Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Tharimmune, Inc. - Common Stock
(NQ:
THAR
)
2.860
-0.100 (-3.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tharimmune, Inc. - Common Stock
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
July 22, 2024
Via
ACCESSWIRE
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
July 17, 2024
Via
ACCESSWIRE
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104
July 16, 2024
Via
ACCESSWIRE
Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor
July 10, 2024
Via
ACCESSWIRE
Tharimmune Announces $2.08 Million Private Placement
June 20, 2024
Via
ACCESSWIRE
Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
March 05, 2024
Via
ACCESSWIRE
Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
February 20, 2024
Via
ACCESSWIRE
Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
January 29, 2024
Via
ACCESSWIRE
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
June 17, 2024
Via
ACCESSWIRE
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
June 10, 2024
Via
ACCESSWIRE
Tharimmune to Present at 2024 BIO International Convention
May 29, 2024
Via
ACCESSWIRE
Tharimmune Announces 1-for-15 Reverse Stock Split
May 22, 2024
Via
ACCESSWIRE
Tharimmune, Inc. (NASDAQ: THAR) Featured in Coverage of the EF Hutton Annual Global Conference
May 16, 2024
Via
Investor Brand Network
Tharimmune To Participate in Two Upcoming Investor Conferences in May
April 30, 2024
Via
ACCESSWIRE
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
April 23, 2024
Via
ACCESSWIRE
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
April 15, 2024
Via
ACCESSWIRE
Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
February 05, 2024
Via
ACCESSWIRE
Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
December 11, 2023
Via
ACCESSWIRE
Tharimmune, Inc. Announces Closing of $11 Million Public Offering
November 30, 2023
Via
ACCESSWIRE
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
November 30, 2023
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to...
Via
Newsfile
BioMedNewsBreaks – Tharimmune Inc. (NASDAQ: THAR) Announces Pricing of $10M Public Offering
November 29, 2023
Via
Investor Brand Network
Tharimmune, Inc. Announces Pricing of $10 Million Public Offering
November 27, 2023
Via
ACCESSWIRE
Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)
November 27, 2023
Via
ACCESSWIRE
Tharimmune Announces 1-for-25 Reverse Stock Split
November 17, 2023
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.